Document is current
Any future updates will be listed below
-
Authors
Avram, Robert
Olgin, Jeffrey E.
Ahmed, Zeeshan
Verreault-Julien, Louis
Wan, Alvin
Barrios, Joshua https://orcid.org/0000-0003-1618-6244
Abreau, Sean https://orcid.org/0000-0002-9426-3789
Wan, Derek
Gonzalez, Joseph E.
Tardif, Jean-Claude https://orcid.org/0000-0002-8200-8983
So, Derek Y.
Soni, Krishan
Tison, Geoffrey H. https://orcid.org/0000-0002-0310-3326
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K23HL135274)
- License Information
-
More Information
Article History
Received: 5 March 2023
Accepted: 21 July 2023
First Online: 11 August 2023
Competing interests
: G.H.T. has received research grants from Myokardia, General Electric and Janssen Pharmaceuticals; he is an advisor to Prolaio Inc. and Viz.ai. J.E.O. has received research funding from the National Institute of Health (U2CEB021881; U54HL143541; 75N91020C00039; R01CA134722), Bill and Melinda Gates Foundation, Patient Centered Outcomes Research Institute and from Samsung and iBeat. R.A., G.H.T. and J.E.O. are co-inventors in the patent pending 63/208,406 (Method and System for Automated Analysis of Coronary Angiograms). J.-C.T. has received research funding from Amarin, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Merck, Novartis and Pfizer; honoraria from DalCor Pharmaceuticals, HLS Pharmaceuticals, Pendopharm and Pfizer; minor equity interest from DalCor Pharmaceuticals; authorship in patents on pharmacogenomics-guided CETP inhibition and use of colchicine after myocardial infarction (J.-C.T. has waived his rights in the colchicine patents and does not stand to gain financially). The other authors declare no competing interests.
